New Indication: Enfortumab Vedotin for Head and Neck Cancer
Study
Open-label, multicohort, phase II study (EV-202)
|
Recurrent/metastatic head and neck cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors
|
Enfortumab vedotin 1.25 mg/kg IV on days 1, 8, and 15 of each 28-day cycle
|
Efficacy
ORR: 23.9%
|
DCR: 56.5%
|
mPFS: 3.9 mos
|
mOS: 6.0 mos
|
mDOR: 9.4 mos (at later data cutoff)
|
Safety
Grade ≥3 AEs: anemia (4.3%), decreased neutrophil count (4.3%)
|
Common AEs (any grade): alopecia (28.3%), fatigue (26.1%), peripheral sensory neuropathy (23.9%)
|
Treatment-related deaths: 4.3%
|
Swiecicki PL,Yilmaz E,Rosenberg AJ Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer
Reviewed by Ulas D. Bayraktar, MD on Mar 2, 2025
